ALK and non-small cell lung carcinoma: In 2020, the combination therapy of nivolumab and ipilimumab (an CTLA-4 inhibitor) was approved for the treatment of patients with metastatic NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic aberrations (45, 46).